RESEARCH TRIANGLE PARK –  Alzheimer’s Disease and dementia have long been feared by many, especially those with first-hand experience. Vik Chandra, CEO and co-founder of uMETHOD is familiar with this disease having seen it in both his grandmother and mother-in-law. According to Chandra, there are 17 and a half million Medicare-aged patients somewhere on a spectrum of cognitive decline, and about 150,000 doctors across the country caring for these patients. He is passionate…READ MORE

Secaucus, NJ and Raleigh, NC – May 4, 2023 – Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, today announced nationwide availability of the RestoreU™ Dementia Panel, a risk assessment and care plan service created by uMETHOD Health, a health technology company specializing in precision medicine for chronic diseases, to help physicians close care gaps for patients with cognitive decline. The RestoreU service employs artificial intelligence…READ MORE

Quest Diagnostics and uMETHOD Health, Inc. are excited to announce the national launch of a robust solution in the fight against dementia. Using a 3-step approach that combines our advanced testing with uMETHOD’s AI-based technology, you can help patients prevent cognitive decline, improve brain health, and maintain independence. Learn more about Quest Diagnostic's Alzheimer's disease testing portfolio at Questforthecure.com or contact a uMETHOD Health representative today.…READ MORE

World Kidney Day has been observed in early March since 2006;  in the US, March is National Kidney Month. Efforts to increase awareness of kidney health are timely, as chronic kidney disease (CKD) affected an estimated 37 million Americans in 2021. Drugs prescribed for common illnesses can increase the risk or severity of CKD. This risk comes in addition to drug-to-drug interactions (DDIs) that might also exacerbate CKD. And unfortunately,…READ MORE

Frontotemporal Dementia (FTD) is a neurodegenerative disease that affects two brain structures:  the frontal lobes and the temporal lobes. The location of damage is distinct from that of Alzheimer’s Disease (AD), which is characterized by the degeneration of the brain structure known as the hippocampus. For each of these conditions, neurodegeneration can be readily quantified by the amount of shrinkage (loss of tissue) in these structures, which can be observed…READ MORE

NASHVILLE, Tenn., Nov. 9, 2022 /PRNewswire/ -- uMETHOD Health, a health technology company specializing in precision medicine for complex diseases, announces a partnership with PathGroup, one of largest independent laboratories in the United States. uMETHOD's AI-based care planning solution, RestoreU, pairs comprehensive testing from PathGroup with actionable treatment recommendations, aimed at lowering patient's risk of developing Alzheimer's and disease progression in its early stages. Read the full release.…READ MORE

uMETHOD Health is a technology company in Research Triangle Park, North Carolina, focused on treating the causes of com­plex diseases.  Its RestoreU METHOD uses patented artificial-intelligence (AI) software to identify the underlying factors that drive someone’s cognitive decline.  This software generates personalized care plans on how to prevent, slow, or even roll-back the progression of cognitive decline.  The software now identifies all the drugs someone may be taking that increase…READ MORE

Dr. Marwan Sabbagh, an Alzheimer’s disease expert and geriatric neurologist at the Barrow Institute in Phoenix, AZ joined Rob Sherman, product manager at Sonora Quest to discuss how the health care community can help combat the rapid rise of Alzheimer's disease in Arizona using progressive and innovative solutions like RestoreU, offered by uMETHOD Health and Sonora Quest Laboratories. The conversation highlights Dr. Sabbagh's use of RestoreU to improve diagnostic confidence…READ MORE